Development and characterization of positively selected brain-adapted SIV by Gaskill, Peter J et al.
BioMed  Central
Page 1 of 15
(page number not for citation purposes)
Virology Journal
Open Access Research
Development and characterization of positively selected 
brain-adapted SIV
Peter J Gaskill, Debbie D Watry, Tricia H Burdo and Howard S Fox*
Address: Department of Neuropharmacology, The Scripps Research Institute, 10550 N. Torrey Pines Road, La Jolla, CA, 92037, USA
Email: Peter J Gaskill - walkin@scripps.edu; Debbie D Watry - watry@scripps.edu; Tricia H Burdo - tburdo@scripps.edu; 
Howard S Fox* - hsfox@scripps.edu
* Corresponding author    
Abstract
HIV is found in the brains of most infected individuals but only 30% develop neurological disease.
Both viral and host factors are thought to contribute to the motor and cognitive disorders resulting
from HIV infection. Here, using the SIV/rhesus monkey system, we characterize the salient
characteristics of the virus from the brain of animals with neuropathological disorders. Nine unique
molecular clones of SIV were derived from virus released by microglia cultured from the brains of
two macaques with SIV encephalitis. Sequence analysis revealed a remarkably high level of similarity
between their env and nef genes as well as their 3' LTR. As this genotype was found in the brains
of two separate animals, and it encoded a set of distinct amino acid changes from the infecting virus,
it demonstrates the convergent evolution of the virus to a unique brain-adapted genotype. This
genotype was distinct from other macrophage-tropic and neurovirulent strains of SIV. Functional
characterization of virus derived from representative clones showed a robust in vitro infection of
174xCEM cells, primary macrophages and primary microglia. The infectious phenotype of this virus
is distinct from that shown by other strains of SIV, potentially reflecting the method by which the
virus successfully infiltrates and infects the CNS. Positive in vivo selection of a brain-adapted strain
of SIV resulted in a near-homogeneous strain of virus with distinct properties that may give clues
to the viral basis of neuroAIDS.
Introduction
As the Acquired Immune Deficiency Syndrome (AIDS)
pandemic continues to grow, the number of people
affected by the neurological complications of human
immunodeficiency virus (HIV) infection expands. Neuro-
logical complications, known collectively as neuroAIDS,
affect approximately 30% of those infected with HIV [1].
Although our knowledge of the process by which HIV
causes brain disease is constantly expanding, we still have
only a limited understanding of the underlying patho-
genic mechanism leading to disease in the central nervous
system (CNS). It has been shown that an increase in the
population of brain macrophages is a significant patho-
logical correlate of neurological disease [2], and that most
strains of HIV isolated from the brains of individuals with
neurological disease are macrophage tropic and utilize the
CCR5 co-receptor [3,4]. Macrophages and microglia,
related cells of monocytic lineage, are the only cell types
consistently infected in the brains of HIV-infected individ-
uals [5]. Damage to neurons is thus indirect, resulting
from effects of viral proteins or products of infected mac-
rophages. The ability of HIV to infect macrophages and
microglia in vitro is predictive of its neuroinvasiveness [6]
and infected monocytes/macrophages are thought to
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carry HIV into the brain as per the Trojan horse hypothesis
[7,8].
Simian immunodeficiency virus (SIV) is closely related to
HIV [9,10] and SIV infection of macaques can generate a
neuroAIDS-like syndrome that mirrors neuroAIDS in
humans, demonstrating the neuropathological hallmarks
of neuroAIDS found in HIV-infected humans along with
cognitive, motor, and neurophysiological impairments
[11-15]. The similarities between HIV- and SIV-induced
neurological disease in humans and macaques, in light of
the ethical and practical limitations of performing neuro-
logical research in humans, make the rhesus macaque an
excellent model for the study of neuroAIDS.
There are a variety of strains and molecular clones of SIV
that have been used to study aspects of AIDS pathogene-
sis, many of which are derived from the SIVmac251 strain
[16]. Of the molecular clones, the most commonly used is
SIVmac239, derived from the SIVmac251 strain by animal
passage and tissue culture proviral DNA cloning [17].
SIVmac239 is highly pathogenic in vivo and displays a very
high infectious capacity for T cells, but not macrophages,
in vitro [17]. Unlike T-cell-tropic strains of HIV, which uti-
lize the CXCR4 but not the CCR5 co-receptor, the T-cell
tropism of SIVmac239 may be based on its inefficient use
of the relatively low cell-surface CD4 density on rhesus
macrophages, rather than co-receptor specificity [18]. Yet
this may not fully explain SIVmac239's lack of productive
macrophage infection, since many studies have found
efficient entry, but post-reverse transcriptional blocks in
the SIVmac239 life cycle in macrophages [19-21].
Other studies have examined the molecular aspects of
virus recovered ex vivo from macrophages late in infection,
revealing specific nucleotide/amino acid changes in viral
genes and their products, which are associated with high
levels of infection of macrophages in vitro [22-25]. In stud-
ying SIV cellular tropism, another commonly used clone
is SIVmac316, isolated from proviral DNA in lung macro-
phages of a macaque that died rapidly after infection with
SIVmac239 [24]. Tropism studies with this clone and oth-
ers like it essentially examine viral revertants, examining
changes in the viral sequence in the context of the back-
bone of SIVmac239 [26].
We have taken an independent approach to examine viral
properties of SIV in the CNS. Using the SIVmac251 stock,
we performed a serial passage of cell-associated virus iso-
lated from the CNS of infected monkeys, followed by pro-
duction of a cell-free stock of virus from in vitro infected
microglia [27,28]. In this manner, we utilized a forward
selection of neuroinvasive variants that exist in, or arose
from, the SIVmac251 stock. In this study we discuss the
development and analysis of SIV clones derived from
virus released by cultured microglia that were isolated
from the brains of monkeys infected with microglia-pas-
saged viral stock. Sequencing and characterization of viral
tropism and infectious phenotype were then undertaken
to analyze genomic and functional characteristics com-
mon to these brain-derived viruses.
Results
Molecular Cloning of Microglia-Derived SIV
A total of 43 clones of the 3' region of SIV were isolated
from viral RNA found in the supernatant of microglia cul-
tures derived from the brains of SIVmac182-infected
macaques 225 and 321. Of these clones, 24 clones were
from animal 225, and 19 clones from animal 321. A por-
tion of gp41 was sequenced in each clone to insure the
identity of the clones and to determine if any of the clones
contained premature truncations due to stop codons in
the gp41 region, a common finding in macrophage-tropic
SIVmac239-derived clones. Sequence analysis confirmed
that all of the clones were SIV, and that none had trunca-
tions in the gp41 region.
Infectivity and Cytopathogenicity
Each of these 43 clones containing the 3' region of SIV was
ligated to the 5' region of SIVmac239, and transfected into
174xCEM cells, a common indicator cell line for SIV infec-
tion. Cultures were observed daily for syncytia formation
and monitored for infectious virus formation by p27Gag
analysis of culture supernatants. Of the 43 viruses, 19 (13
from macaque 225 and 6 from macaque 321) induced
syncytia formation in the cultures and/or tested positive
for p27Gag production in the culture supernatant.
In vitro parameters of cytopathogenicity were then tested,
using cells transfected with SIVmac239 as a positive con-
trol. SIVmac239 led to a very robust infection in 174xCEM
cells, rapidly producing high levels of p27Gag (1.5 ng/ml)
and syncytia. Pronounced cytopathic effects ensued, and
the cells in the SIVmac239-transfected cultures were all
dead by day 11 post-transfection. The microglia-derived
molecular clones could be divided into three groups. A
first group of five clones: 109, 129, 141, 142, and 169,
produced the most consistent and robust infections, with
all clones in this group generating syncytia, consistently
high levels of p27Gag (above 1.5 ng/ml) and high levels
of cell death by day 15 (Table 2).
A second group of six clones: 108, 122, 144, 146, 153 and
159, also produced high levels of p27Gag and syncytia,
although syncytia formation was slower than syncytia for-
mation by the first group and these clones did not induce
large amounts of cell death, with cells just beginning to
die by 15–18 days post transfection. The remaining eight
molecular clones that demonstrated signs of productive
infection were 104, 115, 116, 134, 143, 164, 171 and 173.Virology Journal 2005, 2:44 http://www.virologyj.com/content/2/1/44
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This group of clones 3 was considered least pathogenic of
the three in vitro because they did not cause any detectable
cell death and were unable to consistently generate syncy-
tia and detectable p27Gag levels by day 18 experiments,
although all of them did generate syncytia and high levels
of p27Gag in at least one experiment, with the exception
of 171 and 173, which did not generate syncytia despite
p27Gag production.
Sequence Analysis
The nine clones judged the most pathogenic in vitro were
chosen for complete sequence analysis. These clones
included all five from the most pathogenic group; 109,
129, 141, 142 and 169, as well as clones 108, 122, 153
and 159 from the second group. Clones from the second
group were picked because they generated the highest lev-
els of p27Gag in that group. Of the clones chosen, 108,
109, 122, 129, 141, and 142 were isolated from macaque
225 and clones 153, 159 and 169 were isolated from
macaque 321. We fully sequenced the env and nef genes as
well as the 3' LTR of each of these molecular clones. These
sequences were used to develop a consensus sequence for
all nine of the molecularly derived clones to be used for
further analysis.
The nine clones showed a remarkable degree of similarity
in the three gene products analyzed, with more differences
in the TM portion of Env and in Nef than in the SU por-
tion of Env. The nine clones differed from the consensus
sequence by zero to six amino acids of 1,144 in amino
acids in all three genes sequenced (Table 3). Comparison
with other common molecular clones of SIV that were
also derived from the SIVmac251 stock showed marked
differences from the consensus sequence of the brain-
adapted viruses in these regions (Table 3). The detail of
these differences can be found in Table 4, showing that
the brain-adapted genotype lacks the commonly seen
truncation in gp41, and possesses 18 unique amino acids
across Env and Nef.
Additional sequence analysis was performed on the gp41
cytoplasmic tail regions of SIVmac251, SIVmac182 and
cDNA derived from the supernatant of microglia from
macaques 225 and 321. These reactions were performed
on the cytoplasmic tail because of the variable sequence
and frequent truncations found in this region and used a
different set of primers than previous sequencing reac-
tions in order to serve as independent confirmation of the
observed amino acid changes. The brain-adapted viruses
developed a unique sequence in this area, with 4 synony-
mous and 14 non-synonymous changes in the gp41 cyto-
plasmic tail regions of both 225 and 321 cDNA when
compared with the original progenitor strain SIVmac251.
There were also two synonymous and five non-synony-
mous changes found when comparing 225 and 321 cDNA
with that of their immediate progenitor, SIVmac182. The
synonymous and non-synonymous changes from both
SIVmac251 and SIVmac182 were identical in uncloned
PCR products from both 225 and 321 microglia superna-
tants, and the resulting amino acid changes in gp41 can be
seen in Table 5.
Macrophage Infection
It has previously been shown that a majority of viruses
isolated from the brains of individuals with neurological
disease are macrophage tropic, and the ability to infect
macrophages is thought to be key in the induction of neu-
rological disease. Because the molecularly cloned viruses
were all isolated from the brains of rhesus macaques that
suffered from encephalitis, we hypothesized that these
viruses were macrophage tropic. To test this hypothesis,
Table 1: Sequence of oligonucleotide primers used for reverse 
transcription, PCR, and sequencing of SIV.
Primer Sequence
Reverse Transcription
SIVGSP TGCTAGGGATTTTTCCTGCYTCGGTTT
Nested PCR
6516 CTCGCTTGCTAACTGCA CTTCTAATCATATCTA
Sph2 GCATGCTATAACACATGCTATTGTAAAAAGTGTT
10505 AAGCAGAAAGGGTCCTAACAGACCAGGGTCTTCA
Molecular Clone Sequencing
For 1 AACTCAGTGCCTACCAGATAA
For 2 TGGCATGGTAGGGATAATAGGA
For 3 ATAAAAGAGGGGTCTTTGTGCT
For 4 AACTGCAGAACCTTGCTATCG
For 5 GTTTGATCCAACTCTAGCCTACAC
For 6 ATGACAGGGTTAAAAAGAGACAAGA
For 7 GAATTGGTTTCTAAATTGGGTAGA
For 8 GAGGCACAAATTCAACAAGAGAAG
For 9 CATACAGAAAACAAAATATGGATGA
For 10 TCCTGGTCCTGAGGTGTAATCCTG
Rev 1 CGCAAGAGTCTCTGTCGCAGAT
Rev 2 AGAGGGTGGGGAAGAGAACACTG
Rev 3 ACTTCTCGATGGCAGTGACC
Rev 4 CCAGACATAATGGAGACTGGTAA
Rev 5 AGAGTACCAAGTTTCATTGTACTC
Rev 6 AGGCAAATAAACATTTTTGCCTAC
Rev 7 GAGCGAAATGCAGTGATATTTATACATCAAG
Population PCR and Sequencing
8877For ATAGCTGGGATGTGTTTGGC
8534For GCTGGGATAGTGCAGCAACAGCAAC
8406For CTACTGGTGGCACCTCAAG
9452Rev CGAGTATCCATCTTCCAC
9625Rev CCTACCAAGTCATCATCTTCCTCA
9880Rev ATCCTCCTGTGCCTCATCTG
10203Rev ATCAAGAAAGTGGGCGTTCCCGACCVirology Journal 2005, 2:44 http://www.virologyj.com/content/2/1/44
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Table 2: In vitro syncytia formation and viral antigen production. The molecular clones, derived from microglia of the indicated 
monkey, were tested by transfection and subsequent growth in 174xCEM cells.
Clone Monkey Longest time to Syncytia Formation Longest time to Detectable p27
Group 1
109 225 7 days 7 days
129 225 7 days 7 days
141 225 7 days 7 days
142 225 7 days 7 days
169 321 7 days 7 days
Group 2
108 225 12 days 12 days
122 225 12 days 12 days
144 225 12 days 12 days
146 225 15 days 18 days
153 321 9 days 10 days
159 321 12 days 12 days
Group 3
104 225 18 days 14 days
115 225 18 days 14 days
116 225 18 days 18 days
134 225 18 days 18 days
143 225 Never 18 days
164 321 12 days 12 days
171 321 Never 15 days
173 321 Never 15 days
Control
SIVmac239 4 days 7 days
Table 3: Comparison of encoded amino acids (AA) from clones described here (top) with other SIV molecular clones (bottom). The 
number (#) and percent (%) changes (∆ ) in the indicated regions of Env and Nef are given.
Clone Monkey Derived From #AA ∆  in gp120 #AA ∆  in gp41 #AA ∆  in Nef ∆  consensus in
Env & Nef
108 225 Viral RNA from Microglia supernatant 0 1 0 0.08%
109 225 Viral RNA from Microglia supernatant 1 0 0 0.08%
122 225 Viral RNA from Microglia supernatant 0 0 0 0.00%
129 225 Viral RNA from Microglia supernatant 1 1 0 0.17%
141 225 Viral RNA from Microglia supernatant 1 2 1 0.35%
142 225 Viral RNA from Microglia supernatant 1 0 1 0.17%
153 321 Viral RNA from Microglia supernatant 1 3 2 0.52%
159 321 Viral RNA from Microglia supernatant 0 2 2 0.35%
169 321 Viral RNA from Microglia supernatant 0 2 1 0.26%
SIVmac1A11 251-79 Proviral DNA from Tissue culture cells 28 8* 18 4.72%
SIVmac32H (pJ5) 32H Proviral DNA from Tissue culture cells 24 14 19 4.98%
SIVmac316 316-85 Proviral DNA from Tissue culture cells 19 8* N/A 3.07%**
SIV/17E-Fr 17E Proviral DNA from Brain & Macrophages 22 11* 20 4.63%
SIVmac239 239-82 Proviral DNA from Tissue culture cells 18 14 15 4.11%
*truncated gp41, **Env only.Virology Journal 2005, 2:44 http://www.virologyj.com/content/2/1/44
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we isolated macrophages from rhesus macaque PBMC
and inoculated them with six of the molecularly cloned
viruses. Three of the viruses that were fully sequenced,
clones 108, 122 and 142, were dropped from this analysis
because their sequences were greater than 99% similar to
another clone being used for these infections. In order to
generate more uniform results between experiments, all
inoculations were performed using spinoculation. Spin-
oculation effectively eliminates potential differences in
viral infection resulting from viral attachment to the cell,
because it moves viruses directly onto their cellular targets
[29,30].
Viruses derived from all six of the molecular clones repli-
cated well in macrophages, and while the levels of p27Gag
produced fluctuated between infections, the pattern of
p27Gag production between the six viruses was remarka-
bly consistent between experiments with the exception of
the p27Gag production by clone 153, which induced
strong p27Gag production on day 4 of this experiment,
had reduced levels on day 10, and had inconsistent
p27Gag production in subsequent experiments. Clones
109, 129, and 169 consistently produced the highest lev-
els of p27Gag (Figure 1). Although strong p27Gag pro-
duction was induced by clone153 on day 4 of this
experiment, p27Gag levels were much reduced by day 10,
and p27Gag production with this clone was inconsistent
in subsequent experiments. As controls, the T-cell-tropic
clones SIVmac239 and the molecular clone SIVmac251
were used and neither of these clones was able to produce
detectable p27Gag after ten days, whereas the
SIVmac251stock (the progenitor strain for SIVmac239,
the SIVmac251 molecular clone and our microglia serial
passage) successfully infected macrophages but produced
relatively low levels of p27Gag (data not shown). Based
on these results and the genetic similarity of the brain-
adapted clones, subsequent experiments focused only on
clones 129 and 169 as representatives of this particular
genotype of SIV.
Both the 129 and 169 molecular clones produced a simi-
lar infectious phenotype following spinoculation, pro-
ducing p27Gag levels that peaked early after infection and
then slowly declined (Figure 2). This particular infection
Table 4: Predicted amino acid residue at the indicated location in the SU region of Env. Bold indicates unique amino acids in clones 129 
and 169.
Env – gp120 67 79 127 132 134 135 144 153 176 178 309 382 385 475 511
S I V m a c 2 3 9 V NI S T SMAKDMGDGD
SIVmac316 M N I S T S M A E D M R D G D
S I V 1 7 E - C l M NI S T SMAND I RNGD
SIV17E/Fr M N I S T S M A N D I R D G D
SIVmac32H L E L P A - M T K D M R D G D
SIVmac1A11 L E S A P - M V K D I G D G N
Clone 129 L DS STPVVK G IR D R N
Clone 169 L DS STPVVK G IR D R N
*sequence not available, – no amino acid residue.
Table 5: Predicted amino acid residue at the indicated location in the TM region of Env. Bold indicates unique amino acids in clones 
129 and 169.
Env – gp41 573 631 676 713 734 737 741 751 752 760 764 767 785 802 821 850 855
S I V m a c 2 3 9KKDMQ I PRDSWE SLTGT
SIVmac316 T K D V Q I P G D S W Stop - - - - -
S I V 1 7 E - C lK K N VQ****** ******
SIV17E/Fr K K D M Q I P G D S Stop - - - - - -
S I V m a c 2 5 1KNDMQ I PGDSWE SLTGT
S I V m a c 3 2 HKDDMQ I PGDSWE SLTGT
S I V m a c 1 A 1 1 K K D M S t o p ------ ------
Clone 129 K D D M Q TQG DRWENFART
Clone 169 K D D M Q TQG GRWENFARA
*sequence not available, – no amino acid residue.Virology Journal 2005, 2:44 http://www.virologyj.com/content/2/1/44
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phenotype, an early peak in p27 levels, was seen in all
infections with either of these two viruses, although
SIVmac129 consistently produced higher peak p27 levels
than SIVmac169.
Microglia Infection
Along with perivascular macrophages, microglia are the
most commonly infected cells in the brain [31]. In order
to determine if the molecularly cloned viruses were able to
infect microglia, these cells were isolated from the brains
of 3 animals (uninfected with SIV, but treated with meth-
amphetamine for other studies). The microglia were spin-
oculated with virus prepared from clones129, 169, or
SIVmac239. The molecular clone of SIVmac251 was also
used to infect microglia from two of the three animals.
Viruses from both clones 129 and 169 were able to pro-
ductively infect microglia, producing very high levels of
p27Gag within the first 5 days, and then slowly declining
out to day ten (Figure 3). While the peak levels of p27Gag
production were reached more slowly in microglia than in
macrophages, taking between 4 and 6 days rather than 3
or 4, the pattern of infection was similar to that seen in
macrophage infections with these viruses. SIVmac239 was
Viral replication in macrophages of six brain-adapted clones  on days four (left) and ten (right) days post-inoculation Figure 1
Viral replication in macrophages of six brain-adapted clones 
on days four (left) and ten (right) days post-inoculation. Cul-
tures were inoculated with virus produced from the indi-
cated clones. Culture media was replaced one day before 
collection at the indicated day and a 24-hour supernatant was 
then analyzed by ELISA to determine p27Gag levels.
Daily SIV production in macrophage cultures Figure 2
Daily SIV production in macrophage cultures. Macrophages 
from two different rhesus monkeys (a – 359, b – 420) were 
inoculated with virus produced from the indicated clones. 
Culture media was replaced each day and the removed 
supernatant was analyzed by ELISA to determine 24-hour 
p27Gag levels. This figure is representative of the infectious 
phenotype for these viruses in this cell type seen in four sep-
arate experiments.
Daily SIV production in microglia cultures Figure 3
Daily SIV production in microglia cultures. Microglia were 
inoculated with virus produced from the indicated clones. 
Culture media was replaced each day and the removed 
supernatant was analyzed by ELISA to determine 24-hour 
p27Gag levels in the supernatant on each day of infection. 
This figure is representative of the infectious phenotype of 
these viruses in this cell type in three separate experiments 
using microglia from independent monkeys.Virology Journal 2005, 2:44 http://www.virologyj.com/content/2/1/44
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unable to infect microglia, failing to produce detectable
levels of p27Gag in any of the infections. The SIVmac251
molecular clone was only able to infect microglia at a very
low level, producing detectable p27Gag only sporadically
during the course of infection (Figure 3).
Spread in Macrophage Infection
Because macrophage tropism is a common characteristic
of viruses found in the brains of individuals with neu-
roAIDS, the spread of virus between macrophages may
carry important implications for understanding disease
progression in the CNS. To assess spread of infection
through macrophages, we enumerated the number of
infected cells in cultures of primary macrophages inocu-
lated with the viruses prepared from molecular clones 129
and 169, in comparison to the parental SIVmac251stock.
In order to account for donor-related differences in mac-
rophage infection, we examined infection of monocyte-
derived macrophages in fourteen experiments, utilizing
cells from four different macaques. The percentages of
infected macrophages varied between experiments (most
likely due to host-cell differences or the variability inher-
ent in working with primary cells), but each viral clone
produced infection within 48 hours of inoculation.
Viruses generated from clones 129 and 169 both pro-
duced separate, unique infection patterns in all animals
(Figure 4). In particular, clone 129 followed a similar
infection pattern found by measuring supernatant
p27Gag (shown in Figure 2), showing the highest percent
of infected cells early on (17.1% by day 4). In contrast,
clone 169 manifested the highest percent of infected cells
later (8.2% on day 6) (Figure 4). The SIVmac251stock
showed a very low level of infection, with 3% or less cells
infected each day.
To further examine the behavior of this brain-adapted
phenotype in terms of viral spread, we performed a sec-
ond macrophage infection over a 10-day time course,
again using clones 129 and 169 as well as the SIVmac239
and SIVmac316 viruses, and the parental
SIVmac251stock. Due to the limited number of macro-
phages derived from each animal, infections were only
analyzed by staining and p27Gag analysis on days 1, 4, 7
and 10 post-infection. Since macrophages isolated from
different rhesus macaques vary in their in vitro susceptibil-
ity to infection, in order to account for this variation,
macrophages from macaques with different susceptibili-
ties were used for each experiment. Although the percent-
ages of infected cells (Figure 5A, 5C) and p27Gag levels
(Figure 5B, 5D) varied between animals, the general infec-
tion pattern, with one notable exception, was remarkably
similar.
Macrophages from donor monkey 408 showed no signif-
icant infection by any virus on day one post-inoculation,
with all chambers showing a percentage (<3%) of infected
cells and no detectable p27Gag levels in the supernatant
(Figures 5A,B). Day four post-inoculation was much dif-
ferent, showing increases in percent of cells infected and
p27Gag levels in chambers infected with SIVmac316
(71% of cells infected with p27Gag levels of 11.5 ng/ml)
and clone 129 (30% and 6.1 ng/ml). Chambers inocu-
lated with clone 169, SIVmac239 and SIVmac251stock
had an extremely low infected cell percentage (<1%) and
no detectable p27Gag levels in the supernatant. On day
seven post-inoculation, the SIVmac316-infected cell per-
centage remained constant (66.6%) while p27Gag levels
dropped (4.6 ng/ml). The percentage of infected cells in
chambers infected with clone 129 dropped more than
two-fold (12.8%) and supernatant p27Gag levels in the
supernatant also dropped (0.8 ng/ml). No change was
seen in SIVmac239 and SIVmac251stock infections. Sur-
prisingly, the infected cell percentage in cultures inocu-
lated with clone 169 greatly increased (14.6%), as did
p27Gag levels in the supernatant (1.9 ng/ml). These
Infected cell percentage in macrophage culture Figure 4
Infected cell percentage in macrophage culture. The percent-
age of macrophages infected each in chamber slide culture of 
primary macaque macrophages infected with brain-adapted 
clones 129 and 169 and the SIVmac251stock. In fourteen 
separate experiments, slides with primary macrophages from 
four different macaques were inoculated with SIV and then 
fixed and stained with DAPI and p27Gag at the indicated 
times. Data for each day are the average from these 
experiments.Virology Journal 2005, 2:44 http://www.virologyj.com/content/2/1/44
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trends all continued on day 10, with a greater than 3-fold
increase in infected cell percentage (58.4%) and superna-
tant p27Gag levels (6.2 ng/ml). SIVmac316-infected
chambers had reduced infected cell percentage (42.8%),
Spread and production of five different isolates of SIV in primary macrophages Figure 5
Spread and production of five different isolates of SIV in primary macrophages. Data from two monkeys (A, B – #408; C, D – 
#411) are shown for infected cell percentage (A, C) and supernatant p27Gag (B, D) from triplicate cultures in chamber slides.Virology Journal 2005, 2:44 http://www.virologyj.com/content/2/1/44
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though p27Gag levels in the supernatant increased (6.5
ng/ml). Chambers infected with clone 129 showed both
reduced infected cell percentage (8.1%) and slightly
reduced p27Gag levels in the supernatant (0.7 ng/ml).
There was no change in the chambers infected with
SIVmac239. Chambers inoculated with the
SIVmac251stock showed increased infected cell percent-
age (5.5%) and a large increase in p27Gag levels in the
supernatant (2.7 ng/ml) at this last time point.
Somewhat similar infection trends were seen on infection
of macrophages from macaque 411 (Figure 5C,D). On
day one post-inoculation, infected cell percentages in
chambers inoculated with SIVmac316 (10.1%) and clone
129 (4.1%) were both higher than those seen in the 408
infections, but neither infection generated detectable
p27Gag levels in the supernatant. Inoculation with
SIVmac316 and clone 129 then followed the same general
pattern found in the 408 infections above, with increases
in infected cell percentage and p27Gag levels in the super-
natant on day 4, followed by a decline on days 7 and 10.
Supernatant p27Gag levels were in general lower than
those found from the macrophages from macaque 408.
However, in contrast to the results found in the other
monkey's macrophages, here clone 169 did not lead to
detectable infected cells or p27Gag levels in the
supernatant at any point in the infection. Furthermore a
low infected cell percentage was seen in SIVmac251stock
and SIVmac239 infected chambers on days 4 and 10
respectively, but neither of these cultures had detectable
p27Gag levels at any point during the infection.
Discussion
To improve understanding of the viral factors that allow
certain strains of HIV/SIV to induce brain disease, we ana-
lyzed molecular clones generated from SIVmac251stock
through serial passage in infected microglia in vivo. After
the final passage, several brain-adapted molecular clones
were isolated from two macaques, 225 and 321, both of
whom died with SIVE. Sequence analysis of the env and
nef  genes of these viral clones showed remarkable
genotypic homology, as the all the brain-adapted clones
differed from their consensus sequence by less than
0.55%.
Separate examination of the cytoplasmic tail of gp41 from
uncloned viral sequence derived from the same microglia
supernatant used to isolate the brain-adapted clones pro-
vided independent verification of these similarities. The
uniqueness of this genotype is seen in comparison with
other common SIVs like SIVmac239, SIVmac316 and
SIVmac17E-Fr, as the brain-adapted genotype differs from
the env and nef gene sequences of the other virus by three
to five percent (Tables 3,4,5). Furthermore, uncloned viral
sequence derived from both 225 and 321 microglia
showed a large number of identical non-synonymous
mutations in the gp41 cytoplasmic tail when compared
with both SIVmac251 and SIVmac182.
Because of the way they were derived, the sequential dif-
ferences from other SIVmac251 derived viruses and the
exceptional homology between the separately isolated
viral clones, the amino acid changes in these clones likely
represent positive selection for adaptations beneficial
towards survival and infection in the brain and CNS. The
large number of identical non-synonymous mutations
from the original SIVmac251 strain supports this idea, as
non-synonymous mutations are only maintained if they
are beneficial adaptations. When these brain-adapted
clones are examined in light of their separate derivation
from two different animals and the relative frequency of
mutations during viral infection of macaques, the extraor-
dinary homogeneity and uniqueness of the sequence of
these brain-adapted clones, along with the identical and
numerous non-synonymous mutations found in virus
from both animals, strongly indicates that this genotype
developed as a result of viral adaptation to the unique
environment found in the CNS.
Numerous studies using SIV have linked brain infection to
macrophage tropism [32-34], and indeed, virus from all
of the brain-derived clones were macrophage tropic. Rep-
resentative clones derived from each macaque (clone 129
from macaque 225, and clone 169 from macaque 321),
were further characterized, and found not only to be infec-
tious in primary macaque macrophages, but also in pri-
mary macaque CD4+ T-cells and primary macaque
microglia. In addition to characterizing the tropism of the
brain-adapted clones, the macrophage and microglia
infection experiments also demonstrated a distinct, repro-
ducible infectious phenotype associated with this viral
genotype.
Numerous studies have analyzed macrophage-tropic
viruses found in animals infected with the T-cell tropic
clone SIVmac239, a phenomenon that is thought to be
due to a series of amino acid changes in the envelope
gene. Using site-directed mutagenesis, Mori and col-
leagues found five amino acid changes in the SIV enve-
lope, V67M, K176E, G382R from the SU region and
K573T, R751G from the TM region that increased p27Gag
production in macrophage cultures [24]. Kodama and
colleagues examined 10 viral clones derived from the
brain of macaque 316-85, and found that all contained 9
amino acid changes in the envelope gene, including the
V67M and G382R changes as well as seven additional
changes in the SU region; T158A, D178N, P334L/R,
D385N, V388A and P421S and R751G in the TM region
[35]. As macrophage tropism is thought to be crucial to
viral infection in the brain, the emergence of amino acidVirology Journal 2005, 2:44 http://www.virologyj.com/content/2/1/44
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changes that contribute to this characteristic is not surpris-
ing in clones derived from the brain. Indeed, the brain-
adapted clones from this study were found to contain
numerous changes in Env, including the G382R and
R751G changes mentioned above (see Table 3).
Macrophage tropism alone is not sufficient for induction
of neurological illness [26], and many studies cite specific
genes thought to be important in the induction of CNS
disease. Mankowski and colleagues demonstrated the pri-
macy of the envelope gene in neurovirulence in the devel-
opment of SIV/17E-Fr, and examination of this clone by
Flaherty and colleagues found macrophage tropism asso-
ciated changes V67M, P334R and G382R in the envelope,
along with several unique amino acid changes [23,26].
These and other studies demonstrate that while there is a
group of amino acid changes associated with the macro-
phage tropic aspect of brain adaptation, it is an additional
set of amino acid changes that allow a virus to successfully
adapt to the environment of the brain. The brain-adapted
clones described in this paper are a perfect example of
this, with several macrophage tropism associated changes
in the envelope, along with a group of entirely unique
amino acid changes; seven in gp120 and seven in gp41.
However, other studies of brain adaptation in SIV find
that specific Nef sequences are also important for
infection and replication of virus in the brain, implying
that similar neuroadaptive changes may also occur in the
nef gene [26,36,37]. Barber and colleagues have noted five
amino acid changes in Nef between SIVmac239 and SIV/
17E-Fr, including two, P12S and E150K, that mediate dis-
tinct Nef/kinase associations and may be important in
neuroadaptation [38]. Also a study of four pigtailed
macaques infected with SHIV containing nef from an SIV
background demonstrated that the majority of nef genes
amplified from an animal with neurologic disease
encoded two amino acid changes, T110A and A185T [39].
The brain-adapted genotype described in this paper does
not contain any of the Nef changes seen in SIV/17E-Fr but
it does contain the T110A residue, along with four other
amino acid changes unique to this genotype among the
viruses examined.
It is clear from the number of common changes found in
various brain derived SIV clones that certain amino acid
residues in Env and Nef are important to the adaptation
of SIV to the CNS environment, including, but not limited
to, those changes contributing to macrophage tropism. As
with many derivatives of SIVmac251, the brain-adapted
viruses described here do match the amino acids for sev-
eral of the reversions noted in SIVmac239 described
above, notably G382R and R751G in Env and T110A in
Nef. The brain-adapted genotype described here also con-
tains some amino acid differences from SIVmac251 and
SIVmac239 that match other neurovirulent viruses like
SIV17E/Fr, although it lacks the commonly seen trunca-
tion in the cytoplasmic region of gp41 and contains sev-
eral amino acid changes that are unique to this group of
viruses.
Unlike the macrophage-tropic and neurovirulent variants
of SIVmac239 described above, the brain-adapted viruses
isolated in this study were selected, or evolved from, a
stock which could infect macrophages naturally in the
course of infection, which was then preserved and selected
for by subsequent passage through the brains of other ani-
mals. We had previously reported that analysis of brain
proviral DNA for a portion of gp120 revealed selection of
homogeneous sequences over the course of microglia pas-
sage [27]. Here, we have expanded these studies to the
entire Env as well as Nef, examination of viral RNA, and
characterization of infectious phenotypes in macrophage
and microglia. Unlike many other studies with SIV, the
changes found in the brain-adapted genotype described in
this paper are an example of forward selection, rather than
reversions that function largely in the context of the back-
bone of the non-macrophage-tropic non-brain-derived
strain SIVmac239.
It is interesting to note that three of the amino acid
changes found in gp41 of the brain-adapted clones are not
found in the same region of their immediate progenitor,
SIVmac182, therefore they developed during the course of
infection in each animal. The presence of identical amino
acid changes in viruses derived from two separate animals
indicates that the genotype described by these clones
results from convergent evolution rather than random
mutation, and therefore the particular changes found in
the genomes of these clones may be important to the nat-
ural adaptation of the virus to the brain.
It is worth noting that both clones 129 and 169 show a
distinct, reproducible phenotype of infection character-
ized by an early peak in viral p27 production, usually in
the first 2–4 days, followed by a gradual decline over the
remainder of the experiment. While these clones have
been shown to cause disease in vivo, the presence of this
phenotype in vivo is still uncertain. However, if this phe-
notype does occur during in vivo infection, it could be a
method by which brain-adapted SIV establishes residence
in the brain, using an initial burst of virus to seed macro-
phages and microglia, which, once infected, lie low,
allowing the neutralization sensitive macrophage-tropic
virus to avoid immune detection until virus in the periph-
ery has sufficiently weakened the immune system for suc-
cessful virus replication in the brain. This approach might
be particularly effective for this virus, given its ability to
infect microglia and the low-turnover rate of that cell type,
to establish a viral archive in the brain. However, this phe-Virology Journal 2005, 2:44 http://www.virologyj.com/content/2/1/44
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notype has only been shown to be distinct among the five
viruses tested in these experiments and may also be an
experimental artifact due to spinoculation or another
aspect of our infection protocol, so the relevance of this
particular phenotype to SIV remains uncertain.
Based on the data presented above; the method of isola-
tion, the uniqueness of the Env and Nef sequences and
their derivation through forward evolution in the brain
and unique phenotype and tropism, it is clear that the
genotype represented by the clones described in this study
represents a new, brain-adapted genotype of SIV with a
unique phenotype of infection. Further study of this gen-
otype and its unique phenotype, both alone and in com-
parison with other brain-adapted strains of SIV, will
hopefully generate greater understanding for the viral
basis of brain disease and dementia, providing new targets
and avenues of research in order to more effectively com-
bat this disease.
Methods & Materials
Cell isolation and culture
All cell culture media and components were obtained
from Invitrogen (Carlsbad, California), fetal calf serum
(FCS) from Hyclone (Logan, Utah) and recombinant
human macrophage colony-stimulating factor (M-CSF)
from Peprotech (Rocky Hill, New Jersey). 174xCEM cells
were obtained from the NIH AIDS and Reference Reagent
Program (Germantown, Maryland), and grown in RPMI-
1640 containing 10% FCS, 10 mM Hepes, and 100 U/mL
penicillin, 100 µg/mL streptomycin and 250 ng/mL fung-
izone (added as an antibiotic cocktail called PSF).
Monocyte-derived macrophages were prepared from rhe-
sus peripheral blood mononuclear cells (PBMC). PBMC
were isolated by Histopaque 1077 (Sigma-Aldrich, St.
Louis, Missouri) gradient centrifugation, and cultured at 2
× 106 cells/ml in complete macrophage media (RPMI-
1640, 10% FCS, 5% autologous monkey serum, 10 mM
HEPES, 10 ng/ml M-CSF, 1% PSF). Cultures were incu-
bated briefly with PBS and then washed with serum-free
RPMI-1640 on days 1, 3, and 5 post-isolation to remove
non-adherent cells. After washing on day 5 post-isolation,
cells were washed one additional time with PBS and then
incubated in Versene (Invitrogen) on ice, agitating every
1–2 minutes. Cells were then shaken loose, enumerated
in a Coulter Z2 counter (Beckmann-Coulter, Fullerton,
California) and resuspended in complete macrophage
media. Purity was ascertained by FACS analysis.
To prepare microglia, the meninges, surface vessels, and
choroid plexi were removed from brains taken from sterile
phosphate buffered saline-perfused rhesus monkeys.
Then brain tissue was homogenized with a Tenbroeck tis-
sue homogenizer, and microglia purified by collagenase/
DNase digestion and Percoll gradient centrifugation as
described [28]. Cells were enumerated in a Coulter Z2
counter, resuspended in complete microglia media
(RPMI-1640, 10% FCS, 20 mM HEPES, 50 ng/ml M-CSF),
and plated in 48-well plates at a concentration of 7.5 × 105
cells/well. Purity was ascertained by FACS analysis. Non-
adherent cells are removed by washing 1, 3 and 5 days
after isolation, and microglia used for experiments on day
6 post-isolation.
Animal infection
Two rhesus macaques were infected intravenously with
cell-free stock of SIVmac182, obtained by 3 generations of
in vivo serial passage of SIVmac251 (44, 47). Both of these
animals developed neuroAIDS with SIV encephalitis.
Macaque 225 had a natural, rapid course of disease,
requiring sacrifice at 80 days post-viral inoculation. Mon-
key 321 was treated with an anti-CD8 antibody at the time
of infection [40] and also had a rapid course of disease,
requiring sacrifice at 108 days post-viral inoculation.
Following sacrifice, microglia from both animals were cul-
tured as described above and cell-free supernatant was
drawn from these cultures on days 8 through 12 post-iso-
lation.
Molecular cloning
Nucleic acids were isolated from the supernatants of cul-
tured microglia, isolated from macaques 225 and 321,
using a QIAamp Viral RNA mini kit (QIAGEN, Valencia,
California) and were used to generate viral cDNA using
the primer SIV GSP (see Table 1 for all primer sequences).
Nested PCR were then used to amplify the cDNA, using
the primers 10505 and 6516 for the first round of ampli-
fication, and primers 10505 and Sph2 for the second
round of amplification. The PCR product was analyzed by
gel electrophoresis to insure it was the proper size and
then excised using the crystal violet gel excision system
(Invitrogen). Approximately 10 ng of cDNA was cloned
into the TOPO-XL vector (Invitrogen) and transformed
into Max Efficiency STBL2 cells (Stratagene, La Jolla, Cali-
fornia). Plasmid DNA was then isolated, restriction
mapped, and initially sequenced using primer For8, corre-
sponding to a region of the gp41 gene.
174xCEM Transfection and Infections
Plasmid DNA was prepared in STBL2 cells (Invitrogen)
and then isolated by miniprep (QIAgen). Clones were
prepared for ligation by digestion with SphI, phenol
extraction and ethanol precipitation. Following this prep-
aration, 0.4 µg of the plasmid containing the newly-
derived 3'-regions of the viral cDNA was ligated to 1.6 µg
of an SphI/SalI restriction digest of the previously charac-
terized 5' fragment of the SIV genome, constituting the
first 6516 bp of SIVmac239 (p239SpSp5, NIH AIDS
Research and Reference Reagent Program), which hadVirology Journal 2005, 2:44 http://www.virologyj.com/content/2/1/44
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been subcloned into the Litmus38 vector (New England
BioLabs, Beverly, Massachusetts). This process was also
used to combine the 3' regions of SIVmac239, and the
molecular clone SIVmac251, both originally obtained
from the NIH AIDS Research and Reference Reagent Pro-
gram, with the 5' region of SIVmac239.
The ligation products were transfected into 174xCEM cells
by DEAE-Dextran. Transfections were observed for syncy-
tia for 18 days and supernatant was taken from each cul-
ture periodically for use in p27Gag ELISA (SIV Core
Antigen Assay, Beckmann-Coulter) to test for the presence
of infectious virus. Clones were monitored microscopi-
cally for the speed of syncytia formation and speed of cell
death in culture, and the media was assayed by ELISA for
p27Gag level in order to characterize the robustness of
infection. All transfections were each performed inde-
pendently at least twice, with an extra transfection being
performed on clones with inconsistent results in the first
two transfections.
Viral stocks were produced in 174xCEM cells using either
transfection, as above, or infection, for the uncloned
SIVmac251 stock and a viral stock of the SIVmac239/
316EM*/nef-open molecular clone. SIVmac239/316/
Macropahge Variant is a macrophage tropic derivative of
SIVmac239 (this clone is hereafter referred to as
SIVmac316, kindly provided by Dr. R. Desrosiers, New
England Primate Research Center, Southborough, Massa-
chusetts). Following infection or transfection, when syn-
cytia become prevalent throughout the infected culture,
cells were washed and resuspended in fresh growth media
every twenty-four hours, with the cell-free supernatant
aliquoted and stored at -80°C. Each stock was run in trip-
licate p27Gag ELISA for quantification.
Sequence Analysis
The 3' regions of nineteen molecular clones were com-
pletely and bi-directionally sequenced using a battery of
primers designed to cover the full length of that fragment
of the genome. The group of primers used included M13
Forward and M13 Reverse as well as ten SIV-specific for-
ward primers and seven SIV-specific reverse primers, listed
on Table 1. All sequencing reactions on the molecular
clones were performed at the TSRI Nucleic Acids Core
Facility.
Additional sequencing reactions were performed on
uncloned cDNA prepared from cell-free viral RNA isolated
from SIVmac251 stock, SIVmac182, and from cultured
microglia from macaques 225 and 321. RNA was con-
verted to cDNA using the First Strand cDNA synthesis kit
(Marligen Biosciences, Ijamsville, MD) and amplified by
using the primers 8534For, 8406For, 9880Rev and
10203Rev, followed by purification of the PCR product
and sequence analysis with 8777For, 9452Rev and
9625Rev in order to sequence the gp41 cytoplasmic tail
region (bases 8750–9499). All direct sequencing reactions
of PCR products were performed by Retrogen (San Diego,
California).
Macrophage and Microglia Infection
Macrophages were purified as above, and plated in 48-
well plates at 7.5 × 104 per well. The macrophages were
grown in these plates for one day and then inoculated in
triplicate with 4 ng (p27Gag) of the virus stock in com-
plete macrophage media. Infection was facilitated by spin-
oculation (30). Briefly, virus was added to each well and
plates were centrifuged at 1,200 × g for 2 hours at 25°C.
Plates were then incubated at 37°C for 22 hours, washed
twice with Hanks Balanced Salt Solution (Invitrogen), and
fed with complete media. Every 24 hours, supernatant was
removed and stored at -80°C, while cells were fed with
fresh complete macrophage media.
Microglia were infected following the above spinocula-
tion protocol. Following spinoculation media was col-
lected and replaced with fresh complete microglia media
daily, similar to the collection protocol followed in mac-
rophage infections.
Macrophage chamber slide culture infection and analysis
PBMCs were isolated and enumerated as described above,
and monocytes purified using the MiniMacs magnetic
separation system (Miltenyi Biotech, Cologne, Germany)
using paramagnetic anti-CD11b beads. The cells were
then enumerated and resuspended in complete
macrophage media and plated onto 8-well chamber slides
(Fisher Scientific, Pittsburgh, Pennsylvania) at 105 cells
per well.
Media was changed on day 3 post-isolation, and on day 6
removed and replaced with the viral inoculum containing
6 ng (p27Gag) of virus stock diluted in complete macro-
phage media, performed in triplicate. Slides were incu-
bated for 24 hours at 37°C, after which the supernatant
was gently aspirated, cells washed, and fed with complete
macrophage media. Day one post-inoculation and every
three days following, one set of slides (corresponding to 3
wells for each infecting virus and one uninfected well for
each virus) was processed for staining and the supernatant
from each chamber was carefully aspirated and stored at -
80°C.
Each chamber was then washed once with phosphate
buffered saline (PBS, Invitrogen) and fixed by incubating
20 minutes at room temperature in 3% paraformalde-
hyde/PBS. After fixing, chambers were gently washed with
distilled water and incubated in 5% bovine serum albu-
min (BSA) in PBS for five minutes. Cells were incubatedVirology Journal 2005, 2:44 http://www.virologyj.com/content/2/1/44
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for 1 hour with a 1:100 dilution of FA2 (mouse anti-
p27Gag antibody, originally obtained from the NIH AIDS
Research and Reference Reagent Program) in 5% BSA in
PBS. Following this incubation, chambers were washed
once with 1% BSA in PBS, and incubated for 1 hour with
a 1:500 dilution of rhodamine-conjugated goat-anti-
mouse antibody (Molecular Probes, Eugene, Oregon) in
5% BSA in PBS. Cells were then washed once with PBS
and incubated for 3 minutes with 4,6-diamidino-2-phe-
nylindole dihydrochloride hydrate (DAPI, Sigma-Aldrich)
diluted to 10 ug/mL in PBS. All of these reactions were
performed at room temperature in the dark. Cells were
then gently washed once with PBS, chamber divisions
were removed and coverslips were attached using Vectash-
ield mounting medium (Vector Labs, Burlingame,
California) and sealed with nail polish. Slides were stored
in the dark at 4°C.
One day after staining, each set of slides was assessed by
computer-assisted fluorescence microscopy using the
Axiovision program (Carl Zeiss, AG, Germany). Three 10x
fields were assessed from each chamber using rhodamine
and DAPI filters, generating nine fields per virus per day
examined. Three fields taken of an uninfected control well
were used to control for background fluorescence. All
observation and focusing was performed under DAPI flu-
orescence to avoid experimenter bias. The images were
analyzed using OpenLab (Improvision, Lexington, MA) to
elucidate the total number of cells and infected cells in
each field. The total number of cells per field was deter-
mined by counting the DAPI-stained nuclei, while the
number of infected cells in each field was determined
using Boolean operations to overlay the FA2-Rhodamine
stained viral gag with those nuclei. The number of posi-
tive-staining cells in the control wells was used to account
for background fluorescence.
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